TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications to older adults. It recommends assessing function, nutrition and cognition before treatment and pairing medication with supports such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications safely to older adults, a group underrepresented in clinical trials of these drugs. The paper urges clinicians to assess function, nutrition and cognition before treatment and to account for age-related risks, including frailty and loss of lean muscle.
Published in the Journal of the American Geriatrics Society, the paper was developed by the AGS Healthy Aging Special Interest Group. It applies the Geriatrics 5Ms Framework—Mind, Mobility, Medications, Multicomplexity and Matters Most—to obesity medications, including incretin therapies such as GLP-1 medications.
The authors describe these medicines as offering potential benefits for weight management and glycemic control, as well as other health conditions. Their framework emphasizes that prescribing decisions for older adults should take account of health and functional needs, rather than focusing on weight alone. The report highlights possible concerns including sarcopenia, frailty, lean-muscle loss, malnutrition and dehydration.
Before treatment, the framework recommends evaluating a patient’s functional status, nutritional adequacy and cognitive impairment. It also calls for supportive measures alongside medication, including resistance training and adequate dietary protein. Depending on a patient’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional.
Balancing Weight Treatment With Healthy Aging
The framework addresses a practical gap: clinicians may be asked to consider medicines whose benefits are promising, while evidence from trials may not fully reflect the needs of older patients. The report does not say that age alone should rule out treatment. Instead, it provides a way to weigh potential benefits against concerns that can affect strength, mobility, nutrition and independence.
That broader assessment matters because weight loss is not the only outcome relevant to an older adult. A treatment plan that does not account for food intake, hydration, muscle health or physical function could overlook issues the authors identify as important. Pairing medication with exercise and nutritional support may help clinicians make decisions with a patient’s wider health goals in view.
The approach also places a patient’s priorities within the decision process through the 5Ms framework’s “Matters Most” element. Its practical effect will depend on how clinicians use it in individual care; the publication describes a prescribing framework, not evidence that a specific treatment plan improves outcomes for every older adult.
Products Worth Considering
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms to Medication
The 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—are used in geriatrics to organize care around an older person’s cognitive health, function, medication needs, health complexity and priorities. The new paper applies those considerations to incretin therapy, a category that includes GLP-1 medications acting through gut-derived hormonal pathways.
The report’s focus is on how to prescribe these medicines in older adults, rather than a general review of obesity treatment or a new clinical trial. It organizes practical considerations around cases and emphasizes assessment and co-interventions. The paper is by Elias M. Wisdom and colleagues and was published in the Journal of the American Geriatrics Society in 2026, with DOI 10.1111/jgs.70769.
“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— The AGS paper’s authors
Evidence Gaps and Individual Risk
The source report says older adults are underrepresented in clinical trials, leaving uncertainty about how well trial findings capture the range of health and functional circumstances clinicians encounter in this group. The framework does not provide a single prescribing rule for every older adult, nor does the source report establish that the proposed supports prevent muscle loss or other risks.
The available material does not specify which patients are most likely to benefit, how clinicians should select among particular medications, or what monitoring schedule to use. It also does not provide outcome data from a trial testing the framework itself. Decisions therefore remain individualized, and the report’s recommendations should not be read as a guarantee of benefit or safety for any particular patient.
Using the Framework in Clinical Care
The paper offers clinicians a structured approach to apply during prescribing discussions: assess function, nutrition and cognition, consider the patient’s priorities and potential risks, and decide whether additional professional support is appropriate. The source material does not announce a rollout, implementation deadline or follow-up study.
As the framework is used in practice, questions will include how clinicians adapt its case-based guidance to different patients and whether team-based supports are available. Patients considering obesity medication can discuss their health goals, current medicines, eating and hydration, mobility, and any concerns about strength with their clinician. The authors’ approach calls for those factors to inform the plan rather than treating medication as a decision about weight alone.
Key Questions
Who developed the new framework?
It was developed by the American Geriatrics Society’s Healthy Aging Special Interest Group and published in the Journal of the American Geriatrics Society.
What does the framework recommend before treatment?
It recommends assessing an older adult’s functional status, nutritional adequacy and cognitive impairment before prescribing obesity medication.
Which risks does the paper highlight?
The paper highlights age-related concerns including frailty, sarcopenia, lean-muscle loss, malnutrition and dehydration.
What supports may accompany medication?
The authors identify resistance training and adequate dietary protein as co-interventions. Depending on the person’s needs, care may also include a dietitian, physical therapist, fitness trainer or behavioral health professional.
Does the framework prove these medicines are safe for all older adults?
No. The paper offers prescribing guidance, while older adults remain underrepresented in clinical trials. It does not establish that any medicine or care plan is appropriate for every older adult.
Source: medicalxpress.com
